2244992-76-3
2244992-76-3 结构式
基本信息
化合物CHMFL-PI3KD-317
CHMFL-PI-3KD-317,CHMFLPI3KD317,CHMFL PI3KD 317
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-112608 | CHMFL-PI3KD-317 | 2244992-76-3 | 1 mg | 1360元 |
| 2025/05/22 | HY-112608 | CHMFL-PI3KD-317 CHMFL-PI3KD-317 | 2244992-76-3 | 5 mg | 2800元 |
| 2025/05/22 | HY-112608 | CHMFL-PI3KD-317 | 2244992-76-3 | 10 mM * 1 mLin DMSO | 3043元 |
常见问题列表
|
PI3Kδ 6 nM (IC 50 ) |
PI3Kα 62.6 nM (IC 50 ) |
PI3Kβ 284 nM (IC 50 ) |
PI3Kγ 202.7 nM (IC 50 ) |
PIK3C2B 882.3 nM (IC 50 ) |
Vps34 1801.7 nM (IC 50 ) |
PI4KIIIA 574.1 nM (IC 50 ) |
PI4KIIIB 300.2 nM (IC 50 ) |
CHMFL-PI3KD-317 has antiproliferative effects, with GI 50 s of 3.5 ± 0.8, 4.0 ± 0.9, 4.8 ± 0.2, 3.3 ± 0.2, 3.0 ± 0.4 μM against PF382, NALM-6, MV4-11, MOLM-14 and MOLM-13 cells, respectively.
CHMFL-PI3KD-317 (Compound 15i; 25, 50 and 100 mg/kg/day, p.o., for 14 days) inhibits the growth of the MOLM14 tumor in mice.
CHMFL-PI3KD-317 shows favorable oral bioavailability and acceptable half-life (T
1/2
= 3.28 h) in Sprague-Dawley rats.
| Animal Model: | Female nu/nu mice bearing MOLM-14 tumor xenografts |
| Dosage: | 25, 50 and 100 mg/kg/day |
| Administration: | P.O. for 14 days |
| Result: | Inhibited the growth of the MOLM14 tumor without mortality or obvious weight loss in mice. |